• AG-120 (Ivosidenib) in AML: Applied Workflows and Optimizati

  2026-06-16

  AG-120 (Ivosidenib) empowers researchers to precisely inhibit mutant IDH1 and drive 2-hydroxyglutarate reduction in AML models. This article delivers actionable protocol enhancements, troubleshooting guidance, and the latest insights from CD44-driven metabolic rewiring studies for maximum experimental impact.

• Oltipraz in MASLD: From Nrf2 Activation to Translational Inn

  2026-06-16

  This thought-leadership article explores Oltipraz's unique potential in metabolic associated steatotic liver disease (MASLD) research by bridging its well-characterized role as an Nrf2 pathway activator and phase II enzyme inducer with the emerging landscape of autophagy and ferroptosis modulation. Drawing on mechanistic insights and recent preclinical evidence, we provide strategic guidance for translational researchers seeking to design impactful studies and navigate the evolving competitive landscape. Protocol parameters and key considerations for optimizing Oltipraz assays in liver disease models are included, with a critical outlook on future directions and limitations.

• Gastrointestinal Device Delivery of mRNA-LNPs: Expression &

  2026-06-15

  This study pioneers the systematic evaluation of gastrointestinal (GI) device-mediated delivery of mRNA-lipid nanoparticles (mRNA-LNPs), revealing distinct biodistribution and expression profiles in mice and pigs compared to traditional parenteral routes. The findings inform the development of noninvasive, patient-friendly alternatives for mRNA therapeutics and vaccines.

• Tofacitinib Citrate (CP-690550): JAK3 Inhibition in Immune R

  2026-06-15

  Tofacitinib citrate (CP-690550 citrate) is a nanomolar, selective JAK3 inhibitor with robust activity in immune regulation research. Its mechanism enables precise modulation of lymphocyte signaling pathways and inflammatory responses. This article details its molecular action, application evidence, and integration into advanced research workflows.

• VX-745 and the Future of Dual-Action p38α MAPK Inhibition

  2026-06-14

  This article explores how VX-745, a selective p38α MAPK inhibitor, redefines anti-inflammatory and anti-oncogenic research through dual-action kinase inhibition. By integrating the latest mechanistic insights and translational strategies—including recent discoveries on kinase activation loop dynamics—the article provides actionable guidance for researchers seeking to leverage VX-745’s unique properties in preclinical workflows. Distinct from standard product overviews, the discussion bridges structural biochemistry, experimental best practices, and the next wave of precision-targeted therapies.

• DAPI Solution (1 mg/mL): DNA Staining for Nuclear Visualizat

  2026-06-13

  DAPI Solution (1 mg/mL) is a blue-fluorescent DNA dye used for nuclear visualization and apoptosis detection. Its high affinity for DNA enables robust viability assessment in fixed and apoptotic cells. This article details DAPI’s mechanism, applications, and evidence benchmarks, with protocol guidance for research workflows.

• GW4064 in FXR Signaling: New Insights from Collagen Depositi

  2026-06-12

  Explore how GW4064, a potent non-steroidal FXR agonist, advances metabolic and fibrotic liver research by modulating FXR/TLR4 pathways. This article reveals new practical and mechanistic insights for researchers using GW4064 in cutting-edge assay development.

• Targeted SPP1 Inhibition in TAMs Reduces Tumor Size: Study I

  2026-06-12

  A recent study demonstrates that targeted inhibition of SPP1 in tumor-associated macrophages (TAMs) via small molecule modulators can drive significant tumor regression in preclinical models. This work establishes SPP1 as a direct therapeutic target in the tumor microenvironment, opening new avenues for precise macrophage modulation in oncology research.

• Standardized Whole-Blood Stimulation to Probe Immunometaboli

  2026-06-11

  This protocol study introduces a robust workflow for analyzing immune responses in fresh human whole blood under metabolic modulation. By detailing standardized procedures for stimulation and cytokine quantification, it enables reproducible investigation of how metabolic inhibitors selectively influence immune cell function.

• Applied TUNEL Apoptosis Detection Kit Workflow & Best Practi

  2026-06-11

  Unlock robust, artifact-free apoptosis detection in diverse models using the TUNEL Apoptosis Detection Kit (DAB). This guide translates recent glioma research into stepwise protocols, troubleshooting strategies, and advanced applications for tissue and cell analysis.

• Protoporphyrin IX at the Nexus of Heme, Ferroptosis, and Can

  2026-06-10

  Protoporphyrin IX is emerging as a pivotal molecule at the intersection of heme biosynthesis, iron metabolism, and innovative photodynamic strategies for cancer diagnosis and therapy. This thought-leadership article bridges mechanistic insights and translational opportunities, with strategic guidance for researchers seeking to leverage its unique biochemical and photodynamic properties. By incorporating key advances—such as the METTL16-SENP3-LTF axis in ferroptosis resistance—we outline how the next generation of translational workflows can be designed with enhanced precision, drawing on high-purity reagents like APExBIO's Protoporphyrin IX.

• Redefining Biomolecule Detection: Cy3 TSA Kit in Translation

  2026-06-10

  This article explores how the Cy3 TSA Fluorescence System Kit empowers translational researchers to detect low-abundance biomolecules with unprecedented sensitivity. By weaving mechanistic insight into tyramide signal amplification and referencing recent advances in liver cancer biology, it provides a strategic framework for leveraging fluorescence amplification in immunohistochemistry, immunocytochemistry, and in situ hybridization. The discussion extends beyond standard product claims, addressing protocol optimization and translational impact, and situates the kit within the evolving landscape of biomarker discovery.

• Trelagliptin Succinate: Advanced DPP-4 Inhibition in Diabete

  2026-06-09

  Trelagliptin succinate (SYR-472 succinate) enables once-weekly, potent DPP-4 inhibition for cutting-edge type 2 diabetes and metabolic research. Its robust selectivity, stability, and multi-pathway modulation support reproducible, translational workflows in both glycemic and extra-glycemic experimental models.

• GMDS Drives Core Fucosylation and Tumorigenesis in MYCN-Ampl

  2026-06-09

  This study identifies GDP-mannose 4,6-dehydratase (GMDS) as a direct transcriptional target of N-MYC, demonstrating its critical role in promoting core fucosylation and tumorigenesis in MYCN-amplified neuroblastoma. The findings reveal a novel metabolic vulnerability that could inform targeted therapies for high-risk pediatric cancers.

• Calpeptin: Applied Protocols for Calpain Inhibition in Fibro

  2026-06-08

  Calpeptin empowers researchers with nanomolar precision in modulating calpain-dependent pathways, enabling reproducible investigations in fibrosis and inflammation. This article delivers actionable protocols, advanced troubleshooting, and key workflow strategies, uniquely grounded in recent reference studies and experimental best practices.

16385 records 1/1093 page Next 12345 下5页 Last page